Genotoxicity and carcinogenicity testing of pharmaceuticals: Correlations between induction of DNA lesions and carcinogenic activity

Mutation Research - Reviews in Mutation Research

Volumn 705, Issue 1, 2010, Pages 20-39

  Brambilla, Giovanni ^a   Mattioli, Francesca ^a   Robbiano, Luigi ^a   Martelli, Antonietta ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Carcinogenicity; DNA adducts; DNA repair synthesis; DNA strand breaks; Pharmaceuticals

Indexed keywords

ACARBOSE; ALENDRONIC ACID; ARIPIPRAZOLE; ATENOLOL; BOSENTAN; CAFFEINE; CERIVASTATIN; CHLORAL HYDRATE; CIMETIDINE; CIPROFIBRATE; CITALOPRAM; CLOBAZAM; CLOFIBRATE; CYCLOSPORIN; CYPROTERONE; DANTRON; DIAZEPAM; DOXEFAZEPAM; DOXYLAMINE; DULOXETINE; EPLERENONE; ETHINYLESTRADIOL; ETRETIN; FENOFIBRATE; FINASTERIDE; FLUINDOSTATIN; FORMOTEROL; FROVATRIPTAN; GABAPENTIN; UNINDEXED DRUG;

CARCINOGEN TESTING; CARCINOGENIC ACTIVITY; CARCINOGENICITY; DISORDERS OF DNA SYNTHESIS AND REPAIR; DNA ADDUCT; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG CARCINOGENICITY; GENOTOXICITY; INFORMATION RETRIEVAL; MEDLINE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ANIMALS; CARCINOGENICITY TESTS; DNA ADDUCTS; DNA BREAKS; DNA DAMAGE; DNA REPAIR; DRUG TOXICITY; MUTAGENICITY TESTS; PHARMACEUTICAL PREPARATIONS;

MUS; RATTUS;

EID: 77952584286     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrrev.2010.02.004     Document Type: Review

References (125)

1. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guideline for Industry. S2A. Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals, April 1996.
2. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry. S2B. Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals, July 1997.
3. Müller L., Kikuchi Y., Probst G., Schechtman L., Shimada H., Sofuni T., and Tweats D. ICH-harmonized guidance on genotoxicity testing of pharmaceuticals; evolution, reasoning and impact. Mutat. Res. 436 (1999) 195-225
4. U.S. Department of Health and Human Sciences, Registry of Toxic Effects of Chemical Substances, 1985-1986 ed., U.S. Department of Health and Human Sciences, Washington, 1988.
5. Physicians' Desk Reference, 59th ed., Thomson PDR, Montvale, NJ, USA, 2005.
6. http://www.fda.gov.cder/.
7. http://www.toxnet.nlm.nih.gov/.
8. Von Jacobi H., and Dell H.D. Zur Toxikologie von Acemetacin. Arzneim.-Forsch. 30 (1980) 1398-1417
9. Von Tuschl P., Wottawa A., Heiter A., and Tausch G. Untersuchungen uber die Beeinflussung fon DNS-Reiparatur and DNS-Synthese durch Acemetacin in vitro unt in vivo. Arzneim.-Forsch. 30 (1980) 1418-1421
10. Carlo P., Finollo R., Ledda A., and Brambilla G. Absence of liver DNA fragmentation in rats treated with high oral doses of 32 benzodiazepine drugs. Fundam. Appl. Toxicol. 12 (1989) 34-41
11. Williams G.M., Mori H., and McQueen C.A. Structure-activity relationships in the rat hepatocytes DNA repair test for 300 chemicals. Mutat. Res. 221 (1989) 263-286
12. http://www.potency.berkeley.edu/.
13. Robbiano L., Martelli A., Allavena A., Mazzei M., Gazzaniga G.M., and Brambilla G. Formation of N-nitroso derivatives of six β-adrenergic-blocking agents and their genotoxic effects in rat and human hepatocytes. Cancer Res. 51 (1991) 2273-2279
14. Presta M., Mazzocchi C., Ziliani S., and Ragnotti G. In vitro and in vivo DNA damage of male and female rat liver nuclei by oncogenic and nononcogenic beta blokers. J. Natl. Cancer Inst. 70 (1983) 747-752
15. Zavanella T., Radaelli G., Girotti P., Arias E., Ameri L., Presta M., Mazzoleni G., and Ragnotti G. Evaluation of the tumour-promoting activity of two beta-adrenoreceptor blocking agents, propranolol and atenolol, in liver of Fischer 344 rats. Carcinogenesis 15 (1994) 2531-2539
16. Jackson C.D., and Fishbein L. A toxicological review of beta-adrenergic blockers. Fundam. Appl. Toxicol. 6 (1986) 395-422
17. Hewett C., Ellenberger J., Köllmer H., Kreuzer H., Niggeschulze A., and Stötzer H. Safety assessment of brotizolam. Arzneim.-Forsch. 36 (1986) 592-600
18. International Agency for Research on Cancer (IARC), Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 51: Coffee, Tea, Mate, Methylxantines and Methylglyoxal, IARC, Lyon, France, 1991.
19. Kitamura J., Mori H., Sugie S., and Kawai K. Genetic toxicity of several antihypertensive drugs possessing a hydrazine group. Res. Commun. Chem. Pathol. Pharmacol. 49 (1985) 415-422
20. Wendtlandt W., and Pittner H. Toxikologische Prüfung von Celiprolol, einem kardioselektiven β-Rezeptoren-Blocker. Arzneim.-Forsch. 33 (1983) 41-49
21. Markiewicz V., Tompkins C., Mehdi N., Hubmer S., Payne B.J., and Sumi N. Range finding toxicity and carcinogenicity studies of a new beta-adrenoceptors blocking agent celiprolol in mice. Oyo Yakuri 38 (1989) 421-434
22. International Agency for Research on Cancer (IARC), Monographs on the Evaluation of Carcinogenic Risks of Chemicals to Humans, vol. 72: Hormonal Contraception and Post-Menopausal Hormonal Therapy, IARC, Lyon, France, 1999.
23. Topinka J., Biukova B., Zhu H.K., Andrae U., Neumann I., Schwarz L.R., Werner S., and Wolff T. DNA-damaging activity of the cyproterone acetate analogues chlormadinone acetate and megestrol acetate in rat liver. Carcinogenesis 16 (1995) 1483-1487
24. Martelli A., Mattioli F., Ghia M., Mereto E., and Brambilla G. Comparative study of DNA repair induced by cyproterone acetate, chlormadinone acetate and megestrol acetate in primary cultures of human and rat hepatocytes. Carcinogenesis 17 (1996) 1153-1156
25. International Agency for Research on Cancer (IARC), Monographs on the Evaluation of Carcinogenic Risks of Chemicals to Humans, vol. 21: Sex Hormones, IARC, Lyon, France, 1979.
26. Storer R.D., McKelvey T.W., Kraynak A.R., Elia M.C., Barnum J.E., Harmon L.S., Nichols W.W., and De Luca J.G. Revalidation of the in vitro alkaline elution/rat hepatocyte assay for DNA damage: improved criteria for assessment of cytotoxicity and genotoxicity and results for 81 compounds. Mutat. Res. 368 (1996) 59-101
27. Snyder R.D. A review and investigation into the mechanistic basis of the genotoxicity of antihistamines. Mutat. Res. 411 (1998) 235-248
28. Probst G.S., and Neal S.B. The induction of unscheduled DNA synthesis by antihistamines in primary hepatocytes cultures. Cancer Lett. 10 (1980) 67-73
29. NCI/NTP, Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Toxicology and carcinogenesis studies of chlorpheniramine maleate (CAS No. 113-92-8) in F344/N rats and B6C3F1 mice (gavage studies), Natl. Toxicol. Program Tech. Rep. Ser. No. 317, 1986.
30. Lijinsky W. Induction of tumours in rats by feeding nitrosatable amines togheter with sodium nitrite. Food Chem. Toxicol. 22 (1984) 715-720
31. Struwe M., Greulich K.O., Suter W., and Plappert-Helbig U. The photo comet assay-a fast screening assay for the determination of photogenotoxicity in vitro. Mutat. Res. 632 (2007) 44-57
32. Carlo P., Maura A., Ledda A., Finollo R., Ricci R., and Brambilla G. Lack of DNA fragmentation in rats treated with high oral doses of drugs acting on the central nervous system. Arzneim.-Forsch. 36 (1986) 797-800
33. Nesnow S., Argus M., Bergman H., Chu K., Frith C., Helmes T., McGanghy R., Ray V., Slaga T.J., Tennant R., and Weisburger E. Chemical carcinogens. A review and analysis of the literature of selected chemicals and the establishment of the Gene-Tox Carcinogen Data Base. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat. Res. 185 (1986) 1-195
34. International Agency for Research on Cancer (IARC), Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 50: Pharmaceutical Drugs, IARC, Lyon, France, 1990.
35. Glanert H.P., Reddy J.K., Kennan W.S., Sattler G.L., Rao V.S., and Pitot H.C. Effect of hydrolipidemic peroxisome proliferators on unscheduled DNA synthesis in cultured hepatocytes and mutagenesis in Salmonella. Cancer Lett. 24 (1984) 147-156
36. Rao M.S., Lalwani N.D., Watanabe T.K., and Reddy J.K. Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferators. Cancer Res. 44 (1984) 1072-1076
37. Barzaghi F., Fournex R., and Mantegazza P. Pharmacological and toxicological properties of clobazam (1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-diketo-3H-1,5-benzodi azepine), a new psychotherapeutic agent. Arzneim.-Forsch. 23 (1973) 683-686
38. Miyawaki I., Moriyasu M., Funabashi H., Yasuba M., and Matsuoka N. Mechanism of clobazam-induced thyroidal oncogenesis in male rats. Toxicol. Lett. 145 (2003) 291-301
39. International Agency for Research on Cancer (IARC), Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 66: Some Pharmaceutical Drugs, IARC, Lyon, France, 1996.
40. Blum J.E., Haefely W., Jalfre M., Pole P., and Schärer K. Pharmakologie und Toxikologie des Antiepilecticum Clonazepam. Arzneim.-Forsch. 23 (1973) 377-400
41. Nakajima M., Kitazawa M., Fujiwara M., Inoue H., Asano N., and Yamakawa Y. Mutagenicity studies of clonidine. Iyakuhin Kenkyu 27 (1996) 587-605
42. International Agency for Research on Cancer (IARC), Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 84: Some Drinking-water Disinfectants and Contaminants, including Arsenic, IARC, Lyon, France, 2004.
43. Ryffel B., Donatsch P., Madorin M., Matter B.E., Ruttiman G., Schon H., Stol R., and Wilson J. Toxicological evaluation of cyclosporine A. Arch. Toxicol. 53 (1983) 107-141
44. Martelli A., Mattioli F., Fazio S., Andrae U., and Brambilla G. DNA repair synthesis and DNA fragmentation in primary cultures of human and rat hepatocytes exposed to cyproterone acetate. Carcinogenesis 16 (1995) 1265-1269
45. Kasper P., Tegethoff K., and Mueller L. In vitro mutagenicity studies on cyproterone acetate using female rat hepatocytes for metabolic activation and as indicator cells. Carcinogenesis 16 (1995) 2309-2314
46. Krebs O., Schäfer B., Wolff Th., Oesterle D., Deml E., Sund M., and Favor J. The DNA damaging drug cyproterone acetate causes gene mutation and induces glutathione-S-transferase P in the liver of female Big Blue ™ transgenic F344 rats. Carcinogenesis 19 (1998) 241-245
47. Werner S., Topinka J., Wolff T., and Schwarz L.R. Accumulation and persistence of DNA adducts of the synthesis steroid cyproterone acetate in rat liver. Carcinogenesis 16 (1995) 2369-2372
48. Mueller O., Eckart I., Lutz W.K., and Stopper H. Genotoxicity of the laxative drug components emodin, aloe-emodin, and danthron in mammalian cells: topoisomerase mediated. Mutat. Res. 371 (1996) 165-173
49. Mori H., Kawai K., Ohbayashi F., Kuniyasu T., Yamazaki M., Hamasaki T., and Williams G.M. Genotoxicity of a variety of mycotoxins in the hepatocyte primary culture/DNA repair test using rat and mouse hepatocytes. Cancer Res. 44 (1984) 2918-2923
50. Mori H., Sugie S., Niwa K., Yoshimi N., Tanaka T., and Hirono I. Carcinogenicity of chrysazin in large intestine and liver of mice. Jpn. J. Cancer Res. (GANN) 77 (1986) 871-876
51. Martelli A., Cajelli E., Pino A., Robbiano L., and Brambilla G. DNA damage and repair induced in rat hepatocytes primary cultures by five antihistamines and their nitrosation products. ICRS Med. Sci. 12 (1984) 1054-1055
52. Borelli G., Bertoli D., and Chieco P. Carcinogenicity study of doxefazepam administered in the diet to Sprague-Dawley rats. Fundam. Appl. Toxicol. 15 (1990) 82-92
53. Budroe J.D., Shaddock J.G., and Casciano D.A. A study of the potential genotoxicity of methapyrilene and related antihistamines using the hepatocyte/DNA repair assay. Mutat. Res. 135 (1984) 131-137
54. Jackson C.D., and Sheldon W. Two-year toxicity study of doxylamine succinate in B6C3F1 mice. J. Am. Coll. Toxicol. 12 (1993) 311-321
55. Jackson C.D., and Blackwell B.N. Two-year toxicity study of doxylamine succinate in Fisher 344 rats. J. Am. Coll. Toxicol. 12 (1993) 1-11
56. NCI/NTP, Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Natl. Toxicol. Program Tech. Rep. Ser. No. 446, 1996.
57. Kimura E.T., Fort F.L., Buratto B., Tekeli S., Kesterson J.W., Heyman I.A., and Cusick P.K. Carcinogenic evaluation of estazolam via diet in CD strain Sprague-Dawley rats and B6C3F1 mice for 2 years. Fundam. Appl. Toxicol. 4 (1984) 827-842
58. Bendele R.A., Adams E.R., Hoffman W.P., Gries C.L., and Morton D.M. Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res. 52 (1992) 6931-6935
59. Robison R.L., Suter W., and Cox R.H. Carcinogenicity and mutagenicity studies with fluvastatin, a new entirely synthetic HMG-COA reductase inhibitor. Fundam. Appl. Toxicol. 23 (1994) 9-20
60. Sigler R.E., Gough A.W., and De La Iglesia F.A. Pancreatic acinar cell neoplasia in male Wistar rats following 2 years of gabapentin exposure. Toxicology 98 (1995) 73-82
61. Martelli A., Allavena A., Brambilla Campart G., Canonero R., Ghia M., Mattioli F., Mereto E., Robbiano L., and Brambilla G. In vitro and in vivo testing of hydralazine genotoxicity. J. Pharmacol. Exp. Ther. 273 (1995) 113-120
62. Williams G.M., Mazue G., McQueen C.A., and Shimada T. Genotoxicity of the anthypertensive drugs hydralazine and dihydralazine. Science 210 (1980) 329-330
63. Parodi S., De Flora S., Cavanna M., Pino A., Robbiano L., Bennicelli C., and Brambilla G. DNA-damaging activity in vivo and bacterial mutagenicity of sixteen hydrazine derivatives as related quantitatively to their carcinogenicity. Cancer Res. 41 (1981) 1469-1482
64. De Flora S., Zanacchi P., Bennicelli C., Camoirano A., Cavanna M., Sciabà L., Cajelli E., Faggin P., and Brambilla G. In vivo and in vitro genotoxicity of three antihypertensives hydrazine derivatives (hydralazine, dihydralazine and endralazine). Environ. Mutagen. 4 (1982) 605-619
65. Puri E.C., and Muller D. Testing of hydralazine in in vivo-in vitro hepatocyte assays for UDS and stimulation of replication DNA synthesis. Mutat. Res. 218 (1989) 13-19
66. Toth B. Tumorigenic effect of 1-hydrazinophthalazine hydrochloride in mice. J. Natl. Cancer Inst. 61 (1978) 1363-1365
67. Gershbein L.L., and Rao K.C. Action of hydrazine drugs in tumor-free and 1,2-dimethylhydrazine treated male rats. Oncol. Res. 4 (1992) 121-127
68. Micromedex Thomson Health Care, 22nd ed., USPDI-Drug Information for Health Care Professional, vol. 1, Micromedex Thomson Health Care, Greenwood Village, CO, 2002.
69. Owen G., Hatfield G.K., Pollock J.J., Steinberg A.J., Tucker W.E., and Agersborg Jr. H.P. Toxicity studies of Lorazepam, a new benzodiazepine, in animals. Arzneim.-Forsch. 21 (1971) 1065-1073
70. MacDonald J.S., Gerson R.J., Kornbrust D.J., Kloss M.W., Prahalada S., Berry P.H., Alberts W., and Bokelman D.L. Preclinical evaluation of lovastatin. Am. J. Cardiol. 62 (1988) 16-27
71. Greenman D.L., Allen R., Dahlgren R., Cronin G.M., and Allaben W.T. Chronic toxicity/carcinogenicity study of pyrilamine in B6C3F1 mice. J. Am. Coll. Toxicol. 14 (1995) 148-157
72. Greenman D.L., Cronin G.M., Dahlgren R., Allen R., and Allaben W. Chronic feeding study of pyrilamine in Fisher 344 rats. Fundam. Appl. Toxicol. 25 (1995) 1-8
73. Habs M., Shubik P., and Eisenbrand G. Carcinogenicity of methapyrilene hydrochloride, mepyramine hydrochloride, thenyldiamine hydrochloride, and pyribenzamine hydrochloride in Sprague-Dawley rats. J. Cancer Res. Clin. Oncol. 111 (1986) 71-74
74. Lijinsky W. Chronic toxicity tests of pyrilamine maleate and methapyrilene hydrochloride in F344 rats. Food Chem. Toxicol. 22 (1984) 27-30
75. Althaus F.R., Lawrence S.D., Sattler G.L., and Pitot H.C. DNA damage induced by the antihistaminic drug methapyrilene hydrochloride. Mutat. Res. 103 (1982) 213-218
76. Oberly T.J., Scheuring J.C., Richardson K.A., Richardson F.C., and Garriot M.L. The evaluation of methapyrilene for bacterial mutation with metabolic activation by Aroclor-induced, methapyrilene-induced and noninduced rat-liver S9. Mutat. Res. 299 (1995) 77-84
77. Lijinsky W., and Yamashita K. Lack of binding of methapyrilene and similar antihistamines to rat liver DNA examined by 32P-postlabeling. Cancer Res. 48 (1988) 6475-6477
78. Kubinski H., Gutzke G.E., and Kubinski Z.O. DNA-cell binding (DCB) assay for suspected carcinogens and mutagens. Mutat. Res. 89 (1981) 95-136
79. Casciano D.A., Talaska G., and Clive D. The potent carcinogen methapyrilene induces mutations in the L5178Y mouse lymphoma cells in the apparent absence of DNA adduct formation. Mutat. Res. 263 (1991) 127-136
80. Ashby J., Callander R.D., Paton D., Zeiger E., and Ratpan F. Weak and unexpected mutagenicity to Salmonella of the rat hepatocarcinogen methapyrilene. Environ. Mol. Mutagen. 12 (1988) 243-252
81. Maura A., Carlo P., Ricci R., Cavanna M., and Brambilla G. Absence of DNA damage in mice and rats given high doses of five β-adrenergic-blocking agents. Arzneim.-Forsch. 35 (1985) 1236-1238
82. Fuchs B.A., and Pruett S.B. Morphine induced apoptosis in murine thymocytes in vivo but not in vitro: involvement of both opiate and glucocorticoid receptors. J. Pharmacol. Exp. Ther. 266 (1993) 417-423
83. Friesen M., O'Neill I.K., Malaveille C., Garren L., Hautefeuille A., Cabral J.R.P., Galendo D., Lasne C., Sala M., Chouroulinkov I., Mohr U., Turusov V., Day N.E., and Bartsch H. Characterization and identification of 6 mutagens in opium pyrolysates implicated in oesophageal cancer in Iran. Mutat. Res. 150 (1985) 177-191
84. Sibley P.L., Keim G.R., Kulesza J.S., Murphy B.F., Myhre J.L., Parish H.M., Yoon Y.H., and Zaidi I.H. Preclinical toxicologic evaluation of nadolol, a new β-adrenergic antagonist. Toxicol. Appl. Pharmacol. 44 (1978) 379-389
85. Martelli A., Mattioli F., Mereto E., Brambilla Campart G., Sini D., Bergamaschi G., and Brambilla G. Evaluation of omeprazole genotoxicity in a battery of in vitro and in vivo assays. Toxicology 130 (1998) 29-41
86. Mereto E., Ghia M., Martelli A., and Brambilla G. Lack of evidence of omeprazole genotoxicity in Sprague-Dawley rats. Mutagenesis 8 (1993) 379-386
87. Deutsch W.A., Kukreja A., Shane B., and Hegde V. Phenobarbital, oxazepam and Wyeth 14,643 cause DNA damage as measures by the Comet assay. Mutagenesis 16 (2001) 439-442
88. Bucker J.R., Shackelford C.C., Haseman J.K., Johnson I.D., Kurtz P.J., and Persing R.L. Carcinogenicity studies of oxazepam in mice. Fundam. Appl. Toxicol. 23 (1994) 280-297
89. NCI/NTP, Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Toxicology and carcinogenesis studies of Oxazepam (CAS No. 604-75-1) in Swiss-Webster and B6C3F1 mice (feed studies), Natl. Toxicol. Program Tech. Rep. Ser. No. 443, 1993.
90. NCI/NTP, Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Toxicology and carcinogenesis studies of oxazepam (CAS No. 604-75-1) in F344/N rats (feed studies), Natl. Toxicol. Program Tech. Rep. Ser. No. 485, 1998.
91. Bucker J.R., Haseman J.K., Herbert R.A., and Ryan M.J. Toxicity and carcinogenicity studies of oxazepam in the Fischer 344 rat. Toxicol. Sci. 42 (1998) 1-12
92. Newberne J.W., Newberne P.M., Gibson J.P., Huffman K.W., and Palopoli F.P. Lack of carcinogenicity of oxprenolol, a beta-adrenergic blocking agent. Toxicol. Appl. Pharmacol. 41 (1977) 535-546
93. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 73: Some Chemicals that Cause Tumours of the Kidney or Urinary Bladder in Rodents and some other Substances, IARC, Lyon, France, 1999.
94. Hussain S.S., Al-Dakan A.A., Aboul-Enein H.Y., and Hannan M.A. DNA strand breaks and mutations caused by penbutolol, a beta blocker. Mutat. Res. 204 (1988) 675-682
95. Müller W., Cojocel C., Kramer W., and Mayer D. Absence of genotoxic activity of penbutolol in bacterial and mammalian cell screening systems. Mutat. Res. 242 (1990) 135-142
96. Selden J.R., Dolbeare F., Clair J.H., Miller J.E., McGettigan K., Dijhon J.A., Dysart G.R., and Deluca J.G. Validation of a flow cytometric in vitro DNA repair (UDS) assay in rat hepatocytes. Mutat. Res. 315 (1994) 147-167
97. Tsuda S., Matsusaka N., Madarame H., Ueno S., Susa N., Ispida K., Kawamura N., Sekihashi K., and Sasaki Y.F. The comet assay in eight mouse organ: results with 24 azo compounds. Mutat. Res. 465 (2000) 11-26
98. International Agency for Research on Cancer (IARC), Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 24: Some Pharmaceutical Drugs, IARC, Lyon, France, 1980.
99. G. Brambilla, M. Cavanna, S. De Flora, Genotoxic effects of drugs: experimental findings concerning some chemical families of therapeutic relevance, in: C. Nicolini (Ed.), Chemical Carcinogenesis, Plenum Publishing Corporation, 1982, pp. 193-221.
100. Brambilla G., Cavanna M., Faggin P., Pino A., Robbiano L., Bennicelli C., Zanacchi P., Camoirano A., and De Flora S. Genotoxic activity of five antidepressant hydrazines in a battery of in vivo and in vitro short-term tests. J. Toxicol. Environ. Health 9 (1982) 287-303
101. International Agency for Research on Cancer (IARC), Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 79: Some Thyrotropic Agents, IARC, Lyon, France, 2001.
102. International Agency for Research on Cancer (IARC), Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 76: Some Antiviral and Antineoplastic Drugs, and other Pharmaceutical Agents, IARC, Lyon, France, 2000.
103. Martelli A., Mattioli F., Carrozzino R., Ferraris E., Marchese M., Angiola M., and Brambilla G. Genotoxicity testing of potassium canrenoate in cultured rat and human cells. Mutagenesis 14 (1999) 463-472
104. Martelli A., Carrozzino R., Mattioli F., Bucci G., Lamarino G., and Brambilla G. DNA damage in tissues of rats treated with potassium canrenoate. Toxicology 171 (2002) 95-103
105. Andrews A.W., Lijinsky W., and Snyder S.W. Mutagenicity of amine drugs and their products of nitrosation. Mutat. Res. 135 (1984) 105
106. Madle S., Dean S.W., Andrae U., Brambilla G., Burlinson B., Doolittle D.J., Furihata C., Hertner T., McQueen C.A., and Mori H. Recommendations for the performance of UDS tests in vitro and in vivo. Mutat. Res. 312 (1994) 263-285
107. NCI/NTP, Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S.Department of Health and Human Services, Toxicology and Carcinogenesis studies of promethazine hydrochloride (CAS No. 58-33-3) in F344/N rats and B6C3F1 mice (gavage studies), Natl. Toxicol. Program Tech. Rep. Ser. No. 425, 1993.
108. Weikel Jr. J.H., and Kelly W.A. Tumorigenicity assays of sotalol hydrochloride in rats and mice. J. Clin. Pharmacol. 19 (1979) 591-604
109. Black H.E., Szot R.J., Arthaud L.E., Massa T., Mylecraine L., Klein M., Lake R., Fabry A., Kaminska G.Z., Sinha D.P., and Schwarts E. Preclinical safety evaluation of the benzodiazepine quazepam. Arzneim.-Forsch. 37 (1987) 906-913
110. Maura A., Pino A., Robbiano L., Cajelli E., Finollo R., Cavanna M., and Brambilla G. DNA damage induced by nitrosated ranitidine in cultured mammalian cells. Toxicol. Lett. 18 (1983) 97-102
111. Martelli A., Fugassa E., Voci A., and Brambilla G. Unscheduled DNA synthesis induced by nitrosated ranitidine in primary cultures of rat hepatocytes. Mutat. Res. 122 (1983) 373-376
112. Brambilla G., Cavanna M., Faggin P., Maura A., Pino A., Ricci R., and Robbiano L. Genotoxic effects in rodents given high oral doses of ranitidine and sodium nitrite. Carcinogenesis 4 (1983) 1281-1285
113. Probst G.S., McMahon R.E., Hill L.E., Thompson C.Z., Epp J.K., and Neal S.B. Chemically-induced unscheduled DNA synthesis in primary rat hepatocyte cultures: a comparison with bacterial mutagenicity using 218 compounds. Environ. Mol. Mutagen. 3 (1981) 11-32
114. Mirsalis J.C., Tyson C.K., Steinmetz K.L., Loh E.K., Hamilton C.M., Bakke J.P., and Spalding J.W. Measurement of unscheduled DNA synthesis and S-phase synthesis in rodent hepatocytes following in vivo treatment: testing of 24 compounds. Environ. Mol. Mutagen. 14 (1989) 155-164
115. Tsutsui T., Taguchi S., Hasegawa K., Ide T., Kojima K., Matsumura M., Huff J., and Barrett J.C. Reserpine-induced cell transformation without detectable genetic effects in Syrian hamster embryo cells in culture. Carcinogenesis 15 (1994) 11-14
116. National Cancer Institute, Bioassay of reserpine for possible carcinogenicity, Department of Health, Education, & Welfare Publication No. (NIH) 80-1749, Washington, DC, US Government Printing Office, 1980.
117. Robison R.L., Van Ryzin R.J., Stoll R.E., Jensen R.D., and Bagdon R.E. Chronic toxicity/carcinogenesis study of temazepam in mice and rats. Fundam. Appl. Toxicol. 4 (1984) 394-405
118. Scirus, http://www.scirus.com/.
119. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidelines for Industry, S1A, The Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals, March 1996.
120. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry, S1B, Testing for Carcinogenicity of Pharmaceuticals, July 1997.
121. Brambilla G., Carrozzino R., and Martelli A. Genotoxicity and carcinogenicity studies of benzodiazepines. Pharmacol. Res. 56 (2007) 443-458
122. Brambilla G., and Martelli A. Genotoxicity and carcinogenicity studies of analgesics, anti-inflammatory drugs and antipyretics. Pharmacol. Res. 60 (2009) 1-17
123. Sasaki Y.F., Sekihashi K., Izumiyama F., Nishidate E., Saga A., Ishida R., and Tsuda S.S. The comet assay with multiple mouse organs: comparison of comet assay results and carcinogenicity with 208 chemicals selected from the IARC monographs and U.S. NTP Carcinogenicity Database. Crit. Rev. Toxicol. 30 (2000) 629-799
124. Brambilla G., and Martelli A. Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals. Mutat. Res. 681 (2009) 209-229
125. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic risks to Humans, Suppl. 7: Overall Evaluation of Carcinogenicity: An Updating of IARC Monographs, vols. 1-42, IARC, Lyon, France, 1987.